We are live on ! Find out more
CVS icon

CVS Health

1,654 hedge funds and large institutions have $54.6B invested in CVS Health in 2019 Q2 according to their latest regulatory filings, with 123 funds opening new positions, 754 increasing their positions, 660 reducing their positions, and 154 closing their positions.

New
Increased
Maintained
Reduced
Closed

37% more funds holding in top 10

Funds holding in top 10: 3548 (+13)

14% more repeat investments, than reductions

Existing positions increased: 754 | Existing positions reduced: 660

1% less capital invested

Capital invested by funds: $55.1B → $54.6B (-$425M)

1.44% less ownership

Funds ownership: 78.75%77.31% (-1.4%)

3% less funds holding

Funds holding: 1,7081,654 (-54)

20% less first-time investments, than exits

New positions opened: 123 | Existing positions closed: 154

20% less call options, than puts

Call options by funds: $1.14B | Put options by funds: $1.44B

Holders
1,654
Holders Change
-54
Holders Change %
-3.16%
% of All Funds
35.92%
Holding in Top 10
48
Holding in Top 10 Change
+13
Holding in Top 10 Change %
+37.14%
% of All Funds
1.04%
New
123
Increased
754
Reduced
660
Closed
154
Calls
$1.14B
Puts
$1.44B
Net Calls
-$291M
Net Calls Change
+$32.6M
Name Holding Trade Value Shares
Change
Change in
Stake
William Blair & Company
251
William Blair & Company
Illinois
$15M +$263K +4,878 +2%
XK
252
Xact Kapitalforvaltning
Sweden
$14.9M +$1.91M +35,474 +15%
TIA
253
Tandem Investment Advisors
South Carolina
$14.8M +$1.26M +23,374 +9%
VDI
254
Vaughan David Investments
Illinois
$14.8M +$1.02M +18,878 +7%
DJSG
255
D.J. St. Germain
Massachusetts
$14.7M +$70.5K +1,310 +0.5%
OAM
256
Oppenheimer Asset Management
New York
$14.6M +$6.38M +118,460 +79%
CAG
257
Crestwood Advisors Group
Massachusetts
$14.5M +$1.17M +21,640 +9%
MSL
258
Mackay Shields LLC
New York
$14.5M -$4.35M -80,710 -23%
RT
259
Rockland Trust
Massachusetts
$14.4M +$1.47M +27,302 +12%
TAM
260
Trillium Asset Management
Massachusetts
$14.2M +$5.18M +96,278 +59%
First Manhattan
261
First Manhattan
New York
$14.2M -$17.9M -332,601 -56%
TSW
262
Thompson Siegel & Walmsley
Virginia
$14.1M +$1.3M +24,135 +10%
Los Angeles Capital Management
263
Los Angeles Capital Management
California
$14M -$1.37M -25,480 -9%
SG Americas Securities
264
SG Americas Securities
New York
$13.8M +$4.35M +80,794 +47%
RCM
265
Redwood Capital Management
New York
$13.7M
CTI
266
Community Trust & Investment
Kentucky
$13.7M +$319K +5,919 +2%
TPSF
267
Texas Permanent School Fund
Texas
$13.7M -$97.4K -1,808 -0.7%
MAA
268
Matrix Asset Advisors
New York
$13.6M +$2.23M +41,479 +20%
HCM
269
Hutchinson Capital Management
California
$13.5M -$81.7K -1,517 -0.6%
ASRS
270
Arizona State Retirement System
Arizona
$13.5M -$1.25M -23,208 -9%
Cambridge Investment Research Advisors
271
Cambridge Investment Research Advisors
Iowa
$13.4M +$2.96M +55,013 +29%
URS
272
Utah Retirement Systems
Utah
$13.4M +$139K +2,576 +1%
HC
273
Henshaw Capital
Massachusetts
$13.3M
NIM
274
Northeast Investment Management
Massachusetts
$13.3M -$1.74M -32,400 -12%
CCMIC
275
Cardinal Capital Management Inc (Canada)
Manitoba, Canada
$13.2M -$852K -15,815 -6%

CVS Hedge Fund Activity: Q2 2019 in Review

1,654 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in CVS Health (CVS) for Q2 2019, worth a combined $54.6B — down 0.77% from $55.1B a quarter earlier.

Sellers outnumbered buyers: 154 funds closed out of CVS and 123 opened new positions — a net loss of 31 holders — while 660 trimmed existing stakes and 754 added.

The largest buyer was Nuveen, adding an estimated $648M. The largest seller was T. Rowe Price Associates, cutting an estimated $321M.

  • 1,654 institutional investors held CVS Health (CVS) as of Q2 2019, down from 1,708 in Q1 2019.
  • Funds reported $54.6B of CVS Health stock for Q2 2019, down 0.77% quarter-over-quarter.
  • 123 funds opened new CVS Health positions in Q2 2019 and 154 closed out, a net change of -31 holders.
  • The largest CVS Health buyer in Q2 2019 was Nuveen, an estimated $648M added.
  • The largest CVS Health seller in Q2 2019 was T. Rowe Price Associates, an estimated $321M sold.

Based on aggregated 13F filings for Q2 2019.